Khalil Ahmed, PhD - Minneapolis VA Health Care System
Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Minneapolis VA Health Care System

Menu
Menu
Veterans Crisis Line Badge
My HealtheVet badge
EBenefits Badge
 

Khalil Ahmed, PhD

Dr. Khalil Ahmed

Senior Research Career Scientist, Minneapolis VA Health Care System

Professor of Laboratory Medicine and Pathology, University of Minnesota

Member, Masonic Cancer Center

Member, Graduate Program in MICaB

Telephone:612-467-2594

Email: Khalil.Ahmed@va.gov

 

 

Education

  • BSc Honors, Panjab University
  • MSc Honors, Panjab University
  • PhD, McGill University

Research Interests

  • Androgen action in the prostate, pathobiology of prostate cancer and its targeted therapy using nanomedicine approach
  • Head and Neck cancer therapy using nanomedicine approach
  • Mechanism of cell death and its regulation
  • Protein kinase CK2 signaling in regulation of cell growth and death
  • Biochemistry of membrane transport with focus on mitochondrial function in cell death

Selected Publications

  • Ahmed K, Yenice S, Davis A, Goueli SA: Association of casein kinase 2 (CK-2) with nuclear chromatin in relation to androgenic regulation of rat prostate. Proc Natl Acad Sci USA 90: 4426-4430, 1993.
  • Ahmed K, Gerber DA, Cochet C: Joining the Cell Survival Squad: An Emerging Role for Protein Kinase CK2. Trends in Cell Biology 12: 226-230, 2002.
  • Wang H, Davis A, Yu S, Ahmed K: Response of cancer cells to molecular interruption of the CK2 signal. Mol Cell Biochem 227(1/2): 167-174, 2001.
  • Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, Van Waes C, Ahmed K: Emergence of Protein Kinase CK2 as a Key Target in Cancer Therapy. BioFactors 36(3): 187-195, 2010. [DOI: 10.1002/biof.96]. PMID: 20533398
  • Brown MS, Diallo OT, Hu M, Ehsanian R, Yang X, Arun P, Lu H, Korman V, Unger G, Ahmed K, Van Waes C, Chen Z: CK2 modulation of NF-B, TP53 and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50 nm nanocapsules. Clin Canc Res 16: 2295-2307, 2010. PMID: 20371694 PMID: 20371694 [PubMed - indexed for MEDLINE] PMCID: PMC2861417
  • Trembley JH, Unger G, Tobolt DK, Korman VL, Wang G, Ahmad KA, Slaton J, Kren BT, Ahmed K: Systemic administration of antisense oligonucleotides simultaneously targeting CK2 and ′ reduces primary prostate xenograft tumors in mice. Molec Cell Biochem 356: 21-35, 2011. PMID: 21761204. PMCID: PMC3893918.
  • Trembley JH, Unger GM, Korman VL, Tobolt DK, Kazimierczuk Z, Pinna LA, Kren BT, Ahmed K: Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. Cancer Letters 315: 48–58, 2012. [DOI: 10.1016/j.canlet.2011.10.007]. PMID:22050909
  • Kramerov AA, Ahmed K, Ljubimov AV: Cell rounding in cultured human astrocytes and vascular endothelial cells upon inhibition of CK2 is mediated by actomyosin cytoskeleton alteration. J Cell Biochem. 2012. J Cell Biochem. 13(9):2948-56, 2012. DOI: 10.1002/jcb.24171. PMID: 22552886
  • Trembley JH, Wu J, Unger GM, Kren BT, Ahmed K: CK2 suppression of apoptosis and its implications in cancer biology and therapy. In Pinna LA (Ed.) The Wiley-IUBMB Series on Biochemistry and Molecular Biology: Protein Kinase CK2. ISBN: 978-0-470-96303-6, January 2013, Wiley-Blackwell. Pp 319-333.
  • Unger GM, Kren BT, Korman VL, Kimbrough TG, Vogel RI, Ondrey FG, Trembley JH, Ahmed K: Mechanism and efficacy of sub-50 nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma. Mol Cancer Ther 13:2018-2029, 2014; Published OnlineFirst May 27, 2014; doi:10.1158/1535-7163.MCT-14-0166
  • Qaiser F, Trembley JH, Kren BT, Wu J-J, Naveed AK, Ahmed K: Protein kinase CK2 inhibition induces cell death via early impact on mitochondrial function. J Cell Biochem 115: 2103–2115, 2014. DOI: 10.1002/jcb.24887.
  • Trembley JH, Unger GM, Korman VL, Abedin MJ, Nacusi LP, Vogel RI, Slaton JW, Kren BT, Ahmed K: Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting. 2014. PLoS ONE 9(10): e109970. doi:10.1371/journal.pone.0109970.
  • Ahmed K, Yenice S, Davis A, Goueli SA: Association of casein kinase 2 (CK-2) with nuclear chromatin in relation to androgenic regulation of rat prostate. Proc Natl Acad Sci USA 90: 4426-4430, 1993. 10) Ahmed K, Yenice S, Davis A, Goueli SA: Association of casein kinase 2 (CK-2) with nuclear chromatin in relation to androgenic regulation of rat prostate. Proc Natl Acad Sci USA 90: 4426-4430, 1993.

 

Back
return to top go